Clinical evaluation of CA 15.3 in the post-operative follow-up of breast cancer patients.
In 265 patients operated for breast carcinoma the monoclonal antibody serum test CA 15.3 was predictive of metastatic diffusion of the disease. Its level increased in cases of distant metastasis with no significant difference between multiple and single sites (p = 0.014). The concentration of the marker was higher in 21 (23.8%) patients without nodal involvement and in 19 (27.5%) with nodal involvement (p = 0.193). Our study suggests that CA 15.3 may be an aid in the follow-up of patients with metastatic diffusion of breast cancer.
Scaramuzzi
M
M
Department of Surgery I, Polyclinic, University of Modena, Italy.
Amorotti
C
C
De Palma
M
M
Falchi
A M
AM
Baldini
E
E
De Maria
D
D
Casolo
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000601:surgery; D002277:Carcinoma / Q000097:blood* / Q000556:secondary / Q000601:surgery; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate